Monthly Archives: March 2010

BIO Press Release

For Immediate Release   Contact: Stephanie Fischer     (202) 312-9263 or BIO Statement on Initial Decision in Myriad Genetics Lawsuit Washington, D.C. (March 30, 2010) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement regarding … Continue reading

Posted in Patentable Subject Matter | Tagged , , | Leave a comment

Myriad Ruling: DNA Sequences Are Unpatentable “ Products Of Nature”

In a lengthy opinion released yesterday in Assoc. for Molec. Pathology v. USPTO, __F.Supp.2d___(S.D. N.Y.) (PDF below), the court invalidated claims directed to isolated DNA sequences, as well as to cancer screening methods using them, and even to methods of … Continue reading

Posted in Patentable Subject Matter | Tagged , , , , , , , | 1 Comment

Centocor v. Abbott Labs. – “Antibody Exception” To Written Description Requirement Under Fire

Abbott Laboratories markets a recombinant human antibody, HUMIRA, as a treatment for rheumatoid arthritis. This antibody binds to a receptor on TNF. NYU and Centocor own US Pat No 7070775 which claims an isolated recombinant anti-TNF-a antibody (Ab) comprising a … Continue reading

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , | Leave a comment

Regulatory Framework For Follow-On Biologics In Health Care Bill

In the early evening of March 25, 2010, the House voted, finalizing the budget reconciliation package earlier passed by the Senate, that contained some relatively minor amendments to the version of the Senate Bill that the House passed in the … Continue reading

Posted in Follow-On Biologics | Tagged , , , , , , , | 3 Comments